Blueprint Medicines
169 articles about Blueprint Medicines
-
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
4/18/2024
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update.
-
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
4/11/2024
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 04, 2024
4/4/2024
Blueprint Medicines Corporation, announced that, effective April 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.
-
A year after Roche returned Gavreto’s global rights to Blueprint Medicines, Rigel Pharmaceuticals has acquired the U.S. rights to the FDA-approved treatment for non-small cell lung cancer.
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
2/15/2024
Blueprint Medicines Corporation reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023 and provided financial guidance.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 05, 2024
2/5/2024
Blueprint Medicines Corporation, announced that, effective February 1, 2024, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 1,717 shares of its common stock and an aggregate of 858 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
12/12/2023
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
-
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
12/9/2023
Blueprint Medicines Corporation announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis at the 65th American Society of Hematology Annual Meeting and Exposition being held December 9-12 in San Diego.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 04, 2023
12/4/2023
Blueprint Medicines Corporation, announced that, effective December 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,503 shares of its common stock and an aggregate of 1,251 restricted stock units to two new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
11/28/2023
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m. ET.
-
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis
11/10/2023
Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of AYVAKYT.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 03, 2023
11/3/2023
Blueprint Medicines Corporation, announced that, effective November 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 5,034 shares of its common stock and an aggregate of 2,517 restricted stock units to three new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Reports Third Quarter 2023 Results
10/26/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the third quarter ended September 30, 2023.
-
Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
10/12/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023, to report its third quarter financial results and provide a corporate update.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)-October 6, 2023
10/5/2023
Blueprint Medicines Corporation today announced that, effective October 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,655 shares of its common stock.
-
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 05, 2023
9/5/2023
Blueprint Medicines Corporation, announced that, effective September 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 8,446 shares of its common stock and an aggregate of 4,221 restricted stock units to six new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Reports Second Quarter 2023 Results
8/2/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2023.
-
Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023
7/19/2023
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 2, 2023 , to report its second quarter financial results and provide a corporate update.
-
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
6/3/2023
Blueprint Medicines Corporation announced clinical data for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology Annual Meeting.
-
With the FDA’s approval on Monday, Ayvakit is the first and only treatment for adults with indolent systemic mastocytosis, a rare hematologic disorder, according to Blueprint Medicines.